journal
MENU ▼
Read by QxMD icon Read
search

Sarcoma

journal
https://www.readbyqxmd.com/read/27895527/phase-ii-trial-of-angiotensin-1-7-for-the-treatment-of-patients-with-metastatic-sarcoma
#1
Paul D Savage, James Lovato, K Bridget Brosnihan, Antonius A Miller, W Jeffrey Petty
Background. Angiotensin-(1-7) [Ang-(1-7)] is an endogenous antiangiogenic hormone with anticancer activity. In a phase I study of Ang-(1-7), two of three patients with metastatic sarcoma experienced disease stabilization. This phase II study examined clinical and biomarker outcomes for patients with metastatic sarcoma. Methods. Ang-(1-7) was administered by subcutaneous injection at a dose of 20 mg daily. If excessive toxicities occurred in the first cohort, a dose deescalation cohort was allowed. Blood samples were obtained to measure changes in biomarkers...
2016: Sarcoma
https://www.readbyqxmd.com/read/27843394/trabectedin-followed-by-irinotecan-can-stabilize-disease-in-advanced-translocation-positive-sarcomas-with-acceptable-toxicity
#2
J Herzog, F von Klot-Heydenfeldt, S Jabar, A Ranft, C Rossig, U Dirksen, J Van den Brande, M D'Incalci, I von Luettichau, P J Grohar, W E Berdel, St Burdach
Background. Preclinical data indicate that trabectedin followed by irinotecan has strong synergistic effects on Ewing sarcoma. This is presumably due to hypersensitization of the tumor cells to the camptothecin as an effect of trabectedin in addition to synergistic suppression of EWS-FLI1 downstream targets. A strong effect was also reported in a human rhabdomyosarcoma xenograft. Procedure. Twelve patients with end-stage refractory translocation-positive sarcomas were treated with trabectedin followed by irinotecan within a compassionate use program...
2016: Sarcoma
https://www.readbyqxmd.com/read/27822137/axitinib-has-antiangiogenic-and-antitumorigenic-activity-in-myxoid-liposarcoma
#3
Lauren T Kerr, Jacqueline F Donoghue, Alexander L Wilding, Terrance G Johns
Myxoid liposarcoma is a rare form of soft-tissue sarcoma. Although most patients initially respond well to treatment, approximately 21% relapse, highlighting the need for alternative treatments. To identify novel treatment regimens and gain a better understanding of myxoid liposarcoma tumor biology, we screened various candidate and approved targeted therapeutics and chemotherapeutics against myxoid liposarcoma cell lines. Therapeutics that target angiogenesis showed antitumor activity. The small molecule inhibitor axitinib, which targets angiogenesis by inhibiting the VEGFR and PDGFR families and c-Kit, inhibited cell cycle progression and induced apoptosis in vitro, as well as having significant antitumor activity against MLS 1765 myxoid liposarcoma xenografts in mice...
2016: Sarcoma
https://www.readbyqxmd.com/read/27725792/the-discrepancy-between-patient-and-clinician-reported-function-in-extremity-bone-metastases
#4
Stein J Janssen, Eva A J van Rein, Nuno Rui Paulino Pereira, Kevin A Raskin, Marco L Ferrone, Francis J Hornicek, Santiago A Lozano-Calderon, Joseph H Schwab
Background. The Musculoskeletal Tumor Society (MSTS) scoring system measures function and is commonly used but criticized because it was developed to be completed by the clinician and not by the patient. We therefore evaluated if there is a difference between patient and clinician reported function using the MSTS score. Methods. 128 patients with bone metastasis of the lower (n = 100) and upper (n = 28) extremity completed the MSTS score. The MSTS score consists of six domains, scored on a 0 to 5 scale and transformed into an overall score ranging from 0 to 100% with a higher score indicating better function...
2016: Sarcoma
https://www.readbyqxmd.com/read/27721667/molecular-targets-and-emerging-therapeutic-options-for-uterine-leiomyosarcoma
#5
Heather Miller, Chiemeka Ike, Jennifer Parma, Ramya P Masand, Claire M Mach, Matthew L Anderson
Uterine leiomyosarcoma (uLMS) is an aggressive malignancy characterized by its early metastasis, high rates of recurrence, and poor prognosis. Multiple obstacles complicate the clinical management of uLMS. These include the fact that most uLMS are typically identified only after a woman has undergone hysterectomy or myomectomy, the limited efficacy of adjuvant therapy for early stage disease, and the poor response of metastatic disease to current treatments. Here, we discuss recent insights into the molecular basis of uLMS and discuss emerging options for its clinical management...
2016: Sarcoma
https://www.readbyqxmd.com/read/27703409/current-immunotherapies-for-sarcoma-clinical-trials-and-rationale
#6
Demytra Mitsis, Valerie Francescutti, Joseph Skitzki
Sarcoma tumors are rare and heterogeneous, yet they possess many characteristics that may facilitate immunotherapeutic responses. Both active strategies including vaccines and passive strategies involving cellular adoptive immunotherapy have been applied clinically. Results of these clinical trials indicate a distinct benefit for select patients. The recent breakthrough of immunologic checkpoint inhibition is being rapidly introduced to a variety of tumor types including sarcoma. It is anticipated that these emerging immunotherapies will exhibit clinical efficacy for a variety of sarcomas...
2016: Sarcoma
https://www.readbyqxmd.com/read/27651732/hiv-1-evolutionary-patterns-associated-with-metastatic-kaposi-s-sarcoma-during-aids
#7
Susanna L Lamers, Rebecca Rose, David J Nolan, Gary B Fogel, Andrew E Barbier, Marco Salemi, Michael S McGrath
Kaposi's sarcoma (KS) in HIV-infected individuals can have a wide range of clinical outcomes, from indolent skin tumors to a life-threatening visceral cancer. KS tumors contain endothelial-related cells and inflammatory cells that may be HIV-infected. In this study we tested if HIV evolutionary patterns distinguish KS tumor relatedness and progression. Multisite autopsies from participants who died from HIV-AIDS with KS prior to the availability of antiretroviral therapy were identified at the AIDS and Cancer Specimen Resource (ACSR)...
2016: Sarcoma
https://www.readbyqxmd.com/read/27524931/ewing-s-sarcoma-as-a-second-malignancy-in-long-term-survivors-of-childhood-hematologic-malignancies
#8
Fabian Wolpert, Michael A Grotzer, Felix Niggli, Dieter Zimmermann, Elisabeth Rushing, Beata Bode-Lesniewska
Modern multimodal treatment has significantly increased survival for patients affected by hematologic malignancies, especially in childhood. Following remission, however, the risk of developing a further malignancy is an important issue. The long-term estimated risk of developing a sarcoma as a secondary malignancy is increased severalfold in comparison to the general population. Ewing's sarcoma family encompasses a group of highly aggressive, undifferentiated, intra- and extraosseous, mesenchymal tumors, caused by several types of translocations usually involving the EWSR1 gene...
2016: Sarcoma
https://www.readbyqxmd.com/read/27516726/a-systematic-literature-review-of-adverse-events-associated-with-systemic-treatments-used-in-advanced-soft-tissue-sarcoma
#9
REVIEW
Ann Colosia, Shahnaz Khan, Michelle D Hackshaw, Alan Oglesby, James A Kaye, Jeffrey M Skolnik
This systematic literature review describes adverse events (AEs) among patients with soft tissue sarcoma (STS) who received second-line or later anticancer therapies. Searches were conducted in PubMed, EMBASE, and Cochrane Central Register of Controlled Trials for studies of adults with advanced or metastatic STS who received systemic anticancer therapy before enrollment in a randomized-controlled trial of pazopanib, another targeted cancer agent, or cytotoxic chemotherapy. Of 204 publications identified, seven articles representing six unique studies met inclusion criteria...
2016: Sarcoma
https://www.readbyqxmd.com/read/27478404/surveillance-strategies-for-sarcoma-results-of-a-survey-of-members-of-the-musculoskeletal-tumor-society
#10
David D Greenberg, Brooke Crawford
Background. Surveillance is crucial to oncology, yet there is scant evidence to guide strategies. Purpose. This survey identified sarcoma surveillance strategies for Musculoskeletal Tumor Society (MSTS) members and rationales behind them. Understanding current practice should facilitate studies to generate evidence-based surveillance protocols. Methods. Permission was granted by the Research and Executive Committee of the MSTS to survey members on surveillance strategies. First, the questionnaire requested demographic and clinical practice information...
2016: Sarcoma
https://www.readbyqxmd.com/read/27478403/immediate-versus-delayed-sarcoma-reconstruction-impact-on-outcomes
#11
Kyle J Sanniec, Cristine S Velazco, Lyndsey A Bryant, Nan Zhang, William J Casey Iii, Raman C Mahabir, Alanna M Rebecca
Background. Sarcoma is a rare malignancy, and more recent management algorithms emphasize a multidisciplinary approach and limb salvage, which has resulted in an increase in overall survival and limb preservation. However, limb salvage has resulted in a higher rate of wound complications. Objective. To compare the complications between immediate and delayed (>three weeks) reconstruction in the multidisciplinary limb salvage sarcoma patient population. Methods. A ten-year retrospective review of patients who underwent sarcoma resection was performed...
2016: Sarcoma
https://www.readbyqxmd.com/read/27413360/multimodality-treatment-in-ewing-s-sarcoma-family-tumors-of-the-maxilla-and-maxillary-sinus-review-of-the-literature
#12
REVIEW
David Thorn, Christoph Mamot, Fatime Krasniqi, Frank Metternich, Sven Prestin
The Ewing sarcoma family of tumors (ESFT) encompasses a group of highly aggressive, morphologically similar, malignant neoplasms sharing a common spontaneous genetic translocation that affect mostly children and young adults. These predominantly characteristic, small round-cell tumors include Ewing's sarcoma of the bone and soft tissue, as well as primitive neuroectodermal tumors (PNETs) involving the bone, soft tissue, and thoracopulmonary region (Askin's tumor). Extraosseous ESFTs are extremely rare, especially in the head and neck region, where literature to date consists of sporadic case reports and very small series...
2016: Sarcoma
https://www.readbyqxmd.com/read/27403082/a-phase-i-ii-clinical-trial-of-belinostat-pxd101-in-combination-with-doxorubicin-in-patients-with-soft-tissue-sarcomas
#13
Joanna Vitfell-Rasmussen, Ian Judson, Akmal Safwat, Robin L Jones, Philip Blach Rossen, Maja Lind-Hansen, Poul Knoblauch, Anders Krarup-Hansen
Background. Belinostat is a novel histone deacetylase inhibitor. Primary Objectives. Maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of belinostat (Bel) in combination with doxorubicin (Dox) in solid tumours (phase I) and response rate (RR) in soft tissue sarcomas (phase II). Methods. Bel was administered as a 30-minute IV infusion on days 1-5 and on day 5 with Dox. The dose escalation schedule was as follows: cohort 1: Bel 600 mg/m(2) and 50 mg/m(2) Dox, cohort 2: Bel 600 mg/m(2) and 75 mg/m(2) Dox, cohort 3: Bel 800 mg/m(2) and 75 mg/m(2) Dox, and cohort 4: Bel 1000 mg/m(2) and 75 mg/m(2) Dox...
2016: Sarcoma
https://www.readbyqxmd.com/read/27378829/notch-signaling-mediates-skeletal-muscle-atrophy-in-cancer-cachexia-caused-by-osteosarcoma
#14
Xiaodong Mu, Rashmi Agarwal, Daniel March, Adam Rothenberg, Clifford Voigt, Jessica Tebbets, Johnny Huard, Kurt Weiss
Skeletal muscle atrophy in cancer cachexia is mediated by the interaction between muscle stem cells and various tumor factors. Although Notch signaling has been known as a key regulator of both cancer development and muscle stem cell activity, the potential involvement of Notch signaling in cancer cachexia and concomitant muscle atrophy has yet to be elucidated. The murine K7M2 osteosarcoma cell line was used to generate an orthotopic model of sarcoma-associated cachexia, and the role of Notch signaling was evaluated...
2016: Sarcoma
https://www.readbyqxmd.com/read/27340368/biomechanical-analysis-of-a-novel-acetabulum-reconstruction-technique-with-acetabulum-reconstruction-cage-and-threaded-rods-after-type-ii-pelvic-resections
#15
Vivek Ajit Singh, Hassan Elbahri, Rukmanikanthan Shanmugam
Background. Periacetabular resections with reconstruction has high rates of complications due to the complexity of the reconstruction. We have improvised a novel technique of reconstruction for type II and type II + III pelvic resections with the use of a commercially available acetabulum reconstruction cage (gap II, Stryker) and threaded rods. Objectives. The aim of our study is to determine the biomechanical strength of our reconstruction compared to the traditional cemented total hip replacement (THR) designs in normal acetabulum and establish its mode of failure...
2016: Sarcoma
https://www.readbyqxmd.com/read/27340367/a-comprehensive-single-institutional-review-of-2-years-in-a-designated-fast-track-sarcoma-diagnostic-clinic-linked-with-a-sarcoma-specialist-advisory-group-meeting-the-target-but-failing-the-task
#16
Zoltan Szucs, Dochka Davidson, Han Hsi Wong, Gail Horan, Philip W P Bearcroft, Ian Grant, Robert Grimer, Melanie A Hopper, Helen Hatcher, Helena Earl
Background. National guidelines prompted the implementation of a designated two-week wait referral pathway to facilitate the early diagnosis of sarcomas, to improve treatment outcomes. Methods. Patients referred to the Cambridge Sarcoma Diagnostic Clinic between January 2013 and December 2014 were identified through the electronic appointments system. Information was retrospectively retrieved about patient characteristics and details of the diagnostic pathway. Results. 17.3% of patients referred (69/397) were diagnosed with a malignancy...
2016: Sarcoma
https://www.readbyqxmd.com/read/27313489/overall-survival-and-response-to-systemic-therapy-in-metastatic-extrauterine-leiomyosarcoma
#17
A N Shoushtari, J Landa, D Kuk, A Sanchez, B Lala, N Schmidt, C Okoli, P Chi, M A Dickson, M M Gounder, M L Keohan, A M Crago, W D Tap, S P D'Angelo
Background. Leiomyosarcomas (LMS) represent a heterogeneous subset of soft tissue sarcomas. Factors influencing prognosis for patients with metastatic extrauterine LMS (euLMS) are not well described. Limited data are available regarding responses to systemic therapy. Methods. We collected clinical and pathologic information for all patients with metastatic euLMS seen at Memorial Sloan Kettering Cancer Center between 1989 and 2012. Objective responses to first-line therapy were analyzed for a subset of patients with available baseline and on-treatment imaging using RECIST 1...
2016: Sarcoma
https://www.readbyqxmd.com/read/27293377/an-uncemented-spreading-stem-for-the-fixation-in-the-metaphyseal-femur-a-preliminary-report
#18
Daniel Burger, Matthias Pumberger, Bruno Fuchs
Surgical treatment to restore full range of motion and full weight bearing after extensive femoral bone resection in patients with primary or metastatic femoral tumours is individually challenging. Especially when the remaining distal or proximal bone is very short, a rigid fixation of an implant is difficult to achieve due to the reverse funnel shape of the metaphysis. Herein, we present a novel implant design using a spreading mechanism in the distal part of the prosthesis for rigid, uncemented fixation in the remaining femoral bone after extensive tumour resection of the femur...
2016: Sarcoma
https://www.readbyqxmd.com/read/27199613/extracorporeal-irradiation-and-reimplantation-with-total-hip-arthroplasty-for-periacetabular-pelvic-resections-a-review-of-9-cases
#19
Lester Wai Mon Chan, Jungo Imanishi, Samuel Y Ngan, Sarat Chander, Julie Chu, Renae Thorson, Grant Pang, Peter Choong
We report the early results of nine patients with periacetabular malignancies treated with Enneking and Dunham type 2 resection and reconstruction using extracorporeally irradiated (ECI) tumour bone combined with total hip arthroplasty (THA). Diagnosis was chondrosarcoma in six patients, osteosarcoma in two patients, and metastatic renal cell carcinoma in one patient. All patients underwent surgical resection and the resected specimen was irradiated with 50 Gy in a single fraction before being prepared for reimplantation as a composite autograft...
2016: Sarcoma
https://www.readbyqxmd.com/read/27190495/a-therapeutic-role-for-survivin-in-mitigating-the-harmful-effects-of-ionizing-radiation
#20
Katherine H Carruthers, Gregory Metzger, Eugene Choi, Matthew J During, Ergun Kocak
Background. Radiation therapy is a form of adjuvant care used in many oncological treatment protocols. However, nonmalignant neighboring tissues are harmed as a result of this treatment. Therefore, the goal of this study was to induce the production of survivin, an antiapoptotic protein, to determine if this protein could provide protection to noncancerous cells during radiation exposure. Methods. Using a murine model, a recombinant adenoassociated virus (rAAV) was used to deliver survivin to the treatment group and yellow fluorescence protein (YFP) to the control group...
2016: Sarcoma
journal
journal
32777
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"